ArticleInterdisciplinary cardiovascular and thoracic surgery2023
Mid-term clinical and echocardiographic results of the INSPIRIS RESILIA aortic valve: a retrospective comparison to the Magna Ease.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early and late clinical outcomes and cost-effectiveness of aortic valve replacement using the Inspiris Resilia bioprosthesis : A systematic review and meta-analysis.Journal of cardiothoracic surgery · 2025Pooled it
- Long-term outcomes of surgical aortic valve replacement using a third-generation stented bovine pericardial bioprosthesis in 1907 patients.JTCVS open · 2026Article
- Valve-Related Outcomes up to Six Years of a Next-Generation Bovine Pericardial Bioprosthesis Compared with Its Predecessor: A Propensity-Matched Analysis.Medical sciences (Basel, Switzerland) · 2026Article
- Real-world early- to midterm outcomes of aortic valve replacement using novel tissue technology bioprosthesis at a high-volume center.JTCVS open · 2026Article
- Clinical Outcomes of a New-Generation Surgical Aortic Bioprosthesis: A Noninferiority Study.JTCVS open · 2026Article
- Functional Performance of 2 Different Transcatheter Heart Valve Models as Valve-in-Valve Before and After Expansion of the Inspiris Resilia: An In Vitro Study.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Mid-Term Outcomes After Aortic Valve Replacement in Patients Under 70: A Comparative Study of INSPIRIS RESILIA Versus PERIMOUNT MAGNA EASE Bioprostheses.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Sex-related differences in patient characteristics, practice patterns and outcomes after bioprosthetic and mechanical aortic valve replacement.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Long-term outcomes of the largest (29) Epic Supra aortic valve bioprosthesis: comparing recommended with upsizing implantation.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- The Essential Aortic Valve-in-Valve Transcatheter Aortic Valve Replacement Update: Procedural Strategies and Current Clinical Results.Structural heart : the journal of the Heart Team · 2025Review
- Performance and outcomes of the SAPIEN 3 Ultra RESILIA transcatheter heart valve in the OCEAN-TAVI registry.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesThe INSPIRIS aortic valve combines the RESILIA proprietary tissue preservation process and an expandable stent frame to benefit future transcatheter valve-in-valve procedures. As the INSPIRIS valve became commercially available in 2017, mid-term outcome reports are scarce. We aimed to evaluate mid-term safety and echocardiographic performance of the INSPIRIS valve in comparison to its predecessor, the Carpentier Edwards Perimount Magna Ease (ME).
methodsThis study was a retrospective single-centre study. Clinical results included early postoperative outcomes, mid-term mortality and readmission for cardiovascular cause or stroke. Echocardiographic follow-up (FU) was performed at discharge and 1-3, 6, 12 and 24 months. Clinical end point analyses were accomplished with a propensity score matching analysis and FU echocardiographic data comparisons using pairwise analyses and linear mixed-effect models.
resultsWe included 953 patients who received an INSPIRIS (n = 488) or ME (n = 463) bioprosthesis between January 2018 and July 2021. In the matched population (n = 217 per group), no significant difference in short-term outcomes was observed, survival was similar at 30 months (INSPIRIS: 94% vs ME: 91%, P = 0.89), but freedom from readmission was higher in the INSPIRIS group (94% vs 86%, P = 0.014). INSPIRIS valves had a lower gradient at discharge (∼10 vs 14 mmHg, P < 0.001), 1-3 months (∼10 vs 12 mmHg, P < 0.001) and 24 months (∼11 vs 17 mmHg, P < 0.001) in paired analyses and significantly lower evolution of mean transvalvular gradients compared to ME.
conclusionsThis study represents the largest comparative evaluation of the INSPIRIS to the ME valves, which demonstrated safe clinical outcomes and favourable haemodynamic performance at 2 years. Long-term FU is underway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.